Home › Compare › QNNTF vs EQR

QNNTF vs EQR: Dividend Comparison 2026

QNNTF yields 2000.00% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QNNTF wins by $9939315158.48M in total portfolio value
10 years
QNNTF
QNNTF
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9939315158.53M
Annual income
$9,049,252,674,478,578.00
Full QNNTF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — QNNTF vs EQR

📍 QNNTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQNNTFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QNNTF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
QNNTF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QNNTF
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$7,691,864,773,306,791.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, QNNTF beats the other by $7,691,864,773,302,137.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QNNTF + EQR for your $10,000?

QNNTF: 50%EQR: 50%
100% EQR50/50100% QNNTF
Portfolio after 10yr
$4969657579.29M
Annual income
$4,524,626,337,242,027.00/yr
Blended yield
91.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

QNNTF
No analyst data
Altman Z
-79.6
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QNNTF buys
0
EQR buys
0
No recent congressional trades found for QNNTF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQNNTFEQR
Forward yield2000.00% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$9939315158.53M ✓$47.8K
Annual income after 10y$9,049,252,674,478,578.00 ✓$5,475.61
Total dividends collected$9876141646.27M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: QNNTF vs EQR ($10,000, DRIP)

YearQNNTF PortfolioQNNTF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$210,700$200,000.00$11,380$679.82+$199.3K → QNNTF
2$4,163,767$3,938,317.76$13,014$837.25+$4.15M → QNNTF
3$77,191,133$72,735,902.82$14,961$1,036.20+$77.18M → QNNTF
4$1,342,813,676$1,260,219,163.76$17,297$1,289.22+$1342.80M → QNNTF
5$21,925,333,121$20,488,522,486.99$20,121$1,613.15+$21925.31M → QNNTF
6$336,109,296,351$312,649,189,912.21$23,561$2,030.84+$336109.27M → QNNTF
7$4,838,913,266,619$4,479,276,319,522.88$27,783$2,573.54+$4838913.24M → QNNTF
8$65,446,276,951,058$60,268,639,755,775.59$33,013$3,284.39+$65446276.92M → QNNTF
9$831,834,097,245,644$761,806,580,908,011.90$39,547$4,223.51+$831834097.21M → QNNTF
10$9,939,315,158,531,418$9,049,252,674,478,578.00$47,791$5,475.61+$9939315158.48M → QNNTF

QNNTF vs EQR: Complete Analysis 2026

QNNTF — Stock

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.

Full QNNTF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this QNNTF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QNNTF vs SCHDQNNTF vs JEPIQNNTF vs OQNNTF vs KOQNNTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.